FR2938429A1 - Use of as cosmetic agent of probiotic microorganism in particular of Lactobacillus and Bifidobacterium species genus, for treating scalp disorders e.g. dandruff condition, pruritis or seborrhoeic dermatitis - Google Patents

Abstract

For preventing and/or treating scalp disorders, at least one probiotic microorganism in particular of the Lactobacillusand/or Bifidobacterium speciesgenus, of its fraction and/or metabolite, as cosmetic agent is used. Independent claims are included for following: 1) a cosmetic and/or dermatological composition for preventing scalp disorders comprising effective amount of probiotic microorganism, in particular of the Lactobacillusand/or Bifidobacterium speciesgenus, in combination with an effective amount of at least one active agent selected from antidandruff active agent and/or hydrating active agent; 2) cosmetic process for preventing and/or treating dandruff condition of scalp involving administering a first cosmetic active agent over a first and second consecutive periods of time, where the periods of time together forming a sequence, and at least second cosmetic active agent, topically over a single period of time selected from the first and second periods of time, where the first and second cosmetic active agents being formulated in separate compositions, the first cosmetic active agent being selected from probiotic microorganisms, and the second cosmetic active agent being selected from antidandruff active agents; and 3) cosmetic assembly comprising at least first and a second cosmetic composition, where the first composition containing at least an effective amount of at least first cosmetic active agent, the first cosmetic active agent being Lactobacillus paracasei, and the second composition containing a second cosmetic active agent selected from antidandruff active agents and being administered topically. ACTIVITY : Dermatological; Antipruritic; Antiseborrheic. Test details described, but no results given. MECHANISM OF ACTION : None given.

Description

The present invention aims primarily to provide a new active for the prevention and / or treatment of disorders, particularly aesthetic, of the scalp. In particular, the present invention relates to dandruff disorders of the scalp, in particular of the oily scalp.

The present invention relates to the field of topical products, food supplements or functional foods for the care of the scalp. The scalp is an epidermis with continual renewal, like the rest of the cutaneous tissue, and rich in sebaceous glands. Normally, the scalp is renewed by removing the superficial cells of the skin, insensitively and not visible. However, an excessive renewal of the cells of the stratum corneum of the scalp, for various reasons, can lead to the formation of clusters of large, thick cells, visible to the naked eye, called dandruff. As an example of factors promoting the appearance of dandruff, mention may be made of stress, the winter period, lack of hydration or colonization of the skin or hair follicles by the yeast Malassezia sp .. The genus Malassezia sp . consists of lipophilic yeasts normally present on the skin of humans and certain warm-blooded animals. Their distribution is a function of age, activity of the sebaceous glands, and certain pathologies. Yeast Malassezia sp. It accounts for about 45% of normal commensal flora on the scalp surface in skinless subjects, but can account for 75% of flora in dandruff and up to 85% in associated seborrheic dermatitis. Other germs on the surface of the scalp are micrococci and Propionobacterium. The dandruff states are chronic, frequent, recurrent, and socially disabling states because of their manifest unsightly nature. Many factors can amplify these phenomena and lead to the appearance of additional disorders such as inflammatory conditions of the scalp. These dandruff states and / or inflammatory conditions of the scalp result in an alteration of the barrier function of the epidermis. Moreover, these states can generate itching or pruritus sensations, leading to scraping behaviors that amplify the phenomenon of dandruff. The dandruff conditions of the scalp may be of the fatty type or of the dry type.

The dry dandruff conditions of the scalp are more frequently manifested and are amplified during disorders of the hydration of the skin, and in particular during severe dryness of the epidermis of the scalp. Thus, the treatment of dry dandruff states, and the resolution of their unsightly manifestations, involve being able to sufficiently rehydrate the scalp. Moreover, as indicated previously, the scalp is rich in sebaceous glands. However, it has been observed that dandruff develops more easily in the excessive presence of sebum and is more easily pruriginous. Secretion of sebum is a normal phenomenon and useful for both skin and hair. Sebum protects the scalp and shines the hair by lubricating the cuticle. However, hypersecretion of sebum, or seborrhea, can lead to discomfort, feelings of discomfort, aesthetic disorders or even skin pathology. Thus, excessive secretion of sebum promotes the appearance of a fatty dandruff condition of the scalp or oily dandruff. It has also been recently demonstrated that Malassezia-type yeasts have a significant lipase activity leading to the hydrolysis of triglycerides of sebum to fatty acids. These fatty acids are then capable of causing the dandruff states in susceptible persons, that is to say having an impaired barrier function, and therefore more particularly susceptible to the destructive action of fatty acids on the skin barrier. Thus, the dandruff grows all the more easily that the presence of sebum is important. In addition, they tend to be more easily itchy. Fatty skin states generally respond to different local or systemic antifungal treatments. Thus, various antifungal and anti-seborrheic combination preparations have been proposed to treat severe fatty eye conditions. Anti-fungal treatments demonstrate some efficacy on fatty skin states. However, the efficacy of these treatments is only suspensive and involves rigorous monitoring on the part of the user (frequency of use and sufficient application time).

As a result, many failures occur in the implementation of these treatments and are usually attributable to: poor protocol monitoring; failure to respect the frequency of use; non-cosmetic appearance of the product; irritation of the washing base; poor compliance with the duration of application; weariness.

There remains a need to have new assets likely to have a beneficial cosmetic or therapeutic action on the states of the scalp. There is also a need for assets to restore the ecore flora of the scalp including preventing excessive colonization of the scalp Malassezia sp.

There is also a need for new effective compositions to prevent and / or treat the conditions of the scalp, fat or dry, and which are pleasant and comfortable to implement, thus promoting compliance with the treatment. There is also a need for new active agents to prevent and / or treat pruriginous states and seborrheic dermatitis of the scalp.

There is also a need for new active ingredients to prevent and / or treat inflammatory conditions of the scalp. There is also a need for new actives to hydrate the scalp, and enhance its barrier function properties. The object of the present invention is to satisfy these needs.

Thus, according to a first subject, the invention relates to the cosmetic use of an effective amount of at least one probiotic microorganism, in particular of the genus Lactobacillus sp. and / or Bifidobacterium sp., one of its fractions and / or one of its metabolites, as an agent for preventing and / or treating disorders of the scalp and in particular the dandruff conditions of the scalp.

Unexpectedly, the inventors have observed that a probiotic microorganism, especially of the genus Lactobacillus sp. and / or Bifidobacterium sp., reduces the dandruff states by acting on the hydration and the barrier function of the scalp.

The implementation of such a microorganism promotes the optimization of the assimilation of nutrients provided by the diet in the intestinal mucosa and contributes to promoting the supply of nutrients essential for cell metabolism and the synthesis of the various elements. functional and structural skin. Thus, the strengthening of the barrier functions of the skin makes it possible to reduce the inflammatory conditions of the skin, maintain a balanced barrier, its integrity and the preservation of a balanced ecoflora. The scalp is then less irritated and pruriginous, less fragile and more hydrated and the dandruff states are reduced. Thus, the use of probiotic microorganisms according to the invention, especially of the genus Lactobacillus and / or Bifidobacterium sp. and in particular the strain Lactobacillus paracasei ST11, one of its fractions and / or one of its metabolites makes it possible to restore a normal scalp, in perfect homeostasis. A composition of the invention may advantageously make it possible to restore a balanced ecoflora via the induction of epidermal defense proteins. According to another advantage, a use according to the invention can reduce and / or treat pruritus of the scalp consecutive to the presence of irritating metabolites resulting from the metabolism of lipids of sebum by Malassezia sp. According to another advantage, a use according to the invention can promote the hydration and maintenance of the integrity of the scalp. According to another of its aspects, the present invention relates to the use of an effective amount of at least one probiotic microorganism, in particular of the genus Lactobacillus sp. and / or Bifidobacterium sp. and / or a fraction thereof and / or a metabolite thereof for preparing a pharmaceutical or dermatological composition for preventing and / or treating inflammation of the scalp. In particular, such a composition is effective for treating dry conditions or xerosis of the scalp, pruritus scalp or seborrheic dermatitis of the scalp. A composition of the invention may advantageously be used to prevent and / or treat skin infections, including scalp infections, by Malassezia sp ..

For the purposes of the present invention, the term prevent means to reduce the risk of manifestation of the phenomenon concerned.

According to another of its aspects, the invention relates to a particularly cosmetic process for treating and / or preventing aesthetic disorders of the scalp in a subject comprising at least one step of administering to said subject, at least one effective amount at least one probiotic microorganism, especially of the genus Lactobacillus and / or Bifidobacterium sp. and / or one of its fractions, and / or one of its metabolites. In particular, a method of the invention is advantageously used in individuals having a dandruff condition of the scalp. A use in accordance with the invention may, in addition, comprise the use of at least an effective amount of at least one first probiotic microorganism, in particular of the genus Lactobacillus or Bifidobacterium sp., And / or one of its fractions, and / or one of its metabolites, in combination with an effective amount of at least one second microorganism, especially probiotic, distinct from said first probiotic microorganism. Within the meaning of the invention, the distinct expression of said first probiotic microorganism means that it is possible to distinguish within the composition either two different microorganisms, or two different forms of the same microorganism. Thus, when the second microorganism is, for example, of the genus Lactobacillus or Bifidobacterium sp. and corresponds to the same species as that of the invention, this second microorganism is then present in a form other than the first microorganism.

According to another of its aspects, the present invention relates to a composition, cosmetic and / or dermatological, useful for preventing and / or treating disorders of the scalp, especially the fatty dandruff states of the scalp, comprising in a physiologically acceptable carrier, at minus an effective amount of at least one probiotic microorganism, especially of the genus Lactobacillus sp. and / or Bifidobacterium sp., and / or a fraction thereof and / or one of its metabolites, in combination with an effective amount of at least one active agent selected from an anti-seborrhoeic active agent, a moisturizing active agent, an antidandruff active agent, and mixtures thereof, especially as described below. According to an alternative embodiment of the invention, a microorganism according to the invention can be used orally.

According to another embodiment of the invention, the microorganism according to the invention can be implemented topically.

As specified below, the compositions containing it are formulated to be compatible with the chosen mode of administration. The invention relates to the use of a microorganism according to the invention in the form of a cosmetic or dermatological or pharmaceutical composition.

For the purposes of the present invention, the term "effective amount" means an amount sufficient to obtain the expected effect.

Dandruff States As previously indicated, a scalp with excessive dryness or excessive secretion of sebum may show a dandruff condition which, as the case may be, will be characterized by the presence of dry or greasy dandruff or even itching and / or inflammation of the epidermis. The dry dandruff states translate xerosis of the scalp, possibly associated with an excessively rapid renewal of its stratum corneum. Dry dandruff is usually small in size, white or gray, and spreads over the scalp and clothing that creates an unsightly visual effect. Itching associated with dryness of the scalp can lead to erythema, pruritus, or even an inflammatory condition. Fatty dandruff is one of the forms of seborrheic dermatitis.

Affected individuals have an erythematous scalp covered by large, oily and yellow scales that accumulate to form packs. They have a pruriginous scalp, and often have burning sensations on affected areas. These phenomena can be amplified by the presence of pathogenic microorganisms, including Malassezia sp .. These microorganisms with the property of releasing fatty acids from sebum can alter the barrier function of the epidermis and generate inflammatory conditions. In the dandruff states of the scalp, the skin barrier is unbalanced, its integrity and hydration are altered and its ecoflora disturbed. The skin of the scalp is irritated and itchy, fragile, less hydrated and susceptible to infections. The use of a probiotic microorganism, especially of the genus Lactobacillus and / or Bifidobacterium sp., According to the invention leads to restore hydration and eco-flora and to reduce pruritus of the scalp. This reduction results in a reduction of scalp scratching phases and the resulting alteration of the barrier function. The skin is less irritated and less pruriginous and the presence of dandruff is reduced or eliminated. The uses, processes and compositions according to the invention thus prove to be particularly effective: to prevent and / or treat the disorders, particularly aesthetic, of the scalp associated with excessive dryness, even xerosis, to prevent and / or or treat disorders, especially aesthetic, of the scalp related to excessive excretion and / or secretion of sebum, - to prevent and / or treat the dandruff condition whether dry or greasy scalp, - for to prevent and / or treat pruritic and / or seborrheic dermatitis of the scalp, - to restore a balanced eco-flora of the scalp, - to improve and / or restore the antimicrobial defenses of the scalp

- to improve the comfort of the skins and scalps, - to maintain and / or restore the biomechanical properties of the scalp, - to preserve and / or enhance the integrity of the barrier functions of the skin of the scalp, - to prevent and / or treat inflammatory conditions of the scalp.

Microorganisms A microorganism that is suitable for the invention is a probiotic microorganism, in particular of the genus Lactobacillus and / or Bifodobacterium sp. For the purposes of the present invention, probiotic microorganism is understood to mean a living microorganism which, when consumed in a quantity adequate, has a positive effect on the health of its host (FAO / WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotic in Food Including Fatty Powder, Milk with Live Lactic Acid Bacteria, October 6, 2001), and can in particular improve the intestinal microbial balance. According to a variant of the invention, this microorganism is implemented in an isolated form, that is to say unmixed with one or more compound (s) likely (s) to be associated (s) in his environment original. For the purposes of the invention, the term metabolite refers to any substance derived from the metabolism of the microorganisms considered according to the invention and also having an efficacy for the treatment of fatty or dry scalps. For the purposes of the invention, the term "fraction" more particularly denotes a fragment of said microorganism having an efficacy for the treatment of scalps by analogy with said entire microorganism. The microorganisms that are suitable for the invention may be chosen in particular from ascomycetes such as Saccharomyces, Yarrowia, Kluyveromyces, Torulaspora, Schizosaccharomyces pombe, Debaromyces, Candida, Pichia, Aspergillus and Penicillium, bacteria of the genus Bifidobacterium, Bacteroides, Fusobacterium, Melissococcus, Propionibacterium, Enterococcus, Lactococcus, Staphylococcus, Peptostrepococcus, Bacillus, Pediococcus, Micrococcus, Leuconostoc, Weissella, Aerococcus, Oenococcus and Lactobacillus, and mixtures thereof. Particularly suitable ascomycetes for the present invention are Yarrowia lipolitica and Kluyveromyces lactis, as well as Saccharomyces cereviseae, Torulaspora, Schizosaccharamyces pombe, Candida and Pichia. Specific examples of probiotic microorganisms suitable for the invention are Bifidobacterium adolescentis, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium lactis, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium pseudocatenulatum, Lactobacillus acidophilus (NCFB 1748); Lactobacillus amylovorus, Lactobacillus casei (Shirota), Lactobacillus rhamnosus (GG strain), Lactobacillus brevis, Lactobacillus crispatus, Lactobacillus delbrueckii (subsp bulgaricus, lactis), Lactobacillus fermentum, Lactobacillus helveticus, Lactobacillus gallinarum, Lactobacillus gasseri, Lactobacillus johnsonii (CNCM I-1225 Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus salivarius, Lactobacillus alimentarius, Lactobacillus curvatus, Lactobacillus casei subsp. casei, Lactobacillus sake, Lactococcus lactis, Enterococcus (faecalis, faecium), Lactococcus lactis (subsp lactis or cremoris), Leuconostoc mesenteroides subsp dextranicum, Pediococcus acidilactici, Sporolactobacillus inulinus, Streptococcus salvarius subsp. thermophilus, Streptococcus thermophilus, Staphylococcus carnosus, Staphylococcus xylosus, Saccharomyces (cerevisiae or boulardii), Bacillus (cereus var toyo or subtilis), Bacillus coagulans, Bacillus licheniformis, Escherichia coli strain nissle, Propionibacterium freudenreichii, and mixtures thereof. More particularly, it may be probiotic microorganisms from the group of lactic acid bacteria, such as Lactobacillus and / or Bifidobacterium.

As an illustration of these lactic acid bacteria, Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus casei or Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium animalis, Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, and mixtures thereof. The most suitable species are Lactobacillus johnsonii, Lactobacillus paracasei, Bifidobacterium adolescentis, Bifidobacterium longum respectively deposited according to the Budapest Treaty with the Pasteur Institute (28 rue du Docteur Roux, F-75024 Paris cedex 15) on 30/06/92 , 12/01/99, 15/04/99 and 15/04/99 under the following designations CNCM I-1225, CNCM I-2116, CNCM I-2168 and CNCM I-2170, and the genus Bifidobacterium lactis (Bb 12) (ATCC27536) or Bifidobacterium longum (BB536). The strain of Bifidobacterium lactis (ATCC27536) can be obtained from Hansen (Hansen AIS Chr., 10-12 Boege Alle, PO Box 407, DK-2970 Hoersholm, Denmark).

According to one embodiment, a probiotic microorganism that is suitable for the invention may in particular be a microorganism of the genus Lactobacillus sp. According to a particular embodiment of the invention, the microorganism is different from a Lactobacillus rhamnosus.

Preferably, a microorganism of the genus Lactobacillus sp. suitable for the invention may be selected from the species Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus paracasei, Lactobacillus casei, and mixtures thereof.

According to a preferred embodiment, a microorganism that is suitable for the invention may be a Lactobacillus paracasei. A microorganism that is suitable for the invention may in particular be the strain Lactobacillus paracasei ST11 deposited according to the Budapest Treaty at the Institut Pasteur (28 rue du Docteur Roux, F-75024 Paris cedex 15) on 12/01/99 under the designation CNCM I-2116, and / or a fraction thereof and / or a metabolite thereof. According to one embodiment variant, the invention relates to the use, in addition to a first probiotic microorganism, for example as defined above, of the genus Lactobacillus and / or Bifidobacterium sp., Of at least an effective amount of at least one second microorganism, in particular of probiotic type, and / or one of its fractions and / or one of its metabolites, distinct from said first microorganism. This second microorganism may be chosen especially from ascomycetes such as Saccharomyces, Yarrowia, Kluyveromyces, Torulaspora, Schizosaccharomyces pombe, Debaromyces, Candida, Pichia, Aspergillus and Penicillium, bacteria of the genus Bacteroides, Fusobacterium, Melissococcus, Propionibacterium, Enterococcus, Lactococcus, Staphylococcus , Peptostrepococcus, Bacillus, Pediococcus, Micrococcus, Leuconostoc, Weissella, Aerococcus, Oenococcus, Lactobacillus, Bifidobacterium, and mixtures thereof. According to one embodiment, as the second microorganism, it is the following bacterial and yeast genera that are preferentially used: lactic acid bacteria: which produce by fermentation the sugar of lactic acid. According to their morphology they are divided into two groups: Lactobacillus species: Lactobacillus acidophilus, amylovorus, casei, rhamnosus, brevis, crispatus, delbrueckii (subsp bulgaricus, lactis), fermentum, helveticus, gallinarum, gasseri, johnsonii, plantarum, reuteri, salivarius , alimentarius, curvatus, casei subsp. casei, sake, and Cocci: Enterococcus (faecalis, faecium), Lactococcus lactis (subsp lactis or cremoris), Leuconostoc mesenteroides subsp dextranicum, Pediococcus acidilactici, Sporolactobacillus inulinus, Streptococcus salvarius subsp. thermophilus, Streptococcus thermophilus, Staphylococcus carnosus, Staphylococcus xylosus, bifidobacteria or Bifidobacterium species: Bifidobacterium adolescentis, animalis, bifidum, breve, lactis, longum, infantis, pseudocatenulatum, yeasts: Saccharomyces (cerevisiae or boulardii), other spore-forming bacteria: Bacillus (cereus var toyo or subtilis), Bacillus coagulons, Bacillus licheniformis, Escherichia coli strain nissle, Propionibacterium freudenreichii, and mixtures thereof. More particularly, it may be one of the probiotic microorganisms proposed above, as a specific example of probiotic microorganisms for the first organism. The most suitable species are Lactobacillus johnsonii, Bifidobacterium adolescentis, Bifidobacterium longum and Bifidobacterum lactis NCC 2818 respectively deposited according to the Budapest Treaty with the Pasteur Institute (28 rue du Docteur Roux, F-75024 Paris cedex 15) 30/06 / 92, 12/01/99, 15/04/99, 15/04/99, 07/06/05 under the following designations CNCM I-1225, CNCM I-2168 and CNCM I-2170 and CNCM I-3446, and the genus Bifidobacterium longum (BB536), and mixtures thereof.

According to a particular embodiment, the second probiotic microorganism is of the genus Lactobacillus species, in particular of the species Lactobacillus johnsonii, one of its fractions and / or one of its metabolites. It may in particular be the species Lactobacillus johnsonii respectively deposited according to the Budapest Treaty at the Pasteur Institute (28 rue du Docteur Roux, 20 F-75024 Paris cedex 15) on 30/06/92, under the designation CNCM I61225. A microorganism of the invention may be formulated in a composition in a proportion of at least 0.0001% (expressed in dry weight), in particular in a proportion of 0.0001 to 20% and more particularly in a proportion of 0.001 to 15%. by weight, in particular from 0.01 to 10% by weight, and especially from 0.1% to 2% by weight relative to the total weight of the composition. In general, a composition according to the invention and in particular that intended to be administered orally may comprise, for living microorganisms, from 103 to 1015 cfu / g, in particular from 105 to 10 6 cfu / g and more particularly from 10 to 10 CFU / g of microorganisms per gram of carrier or equivalent doses calculated for inactive or dead microorganisms or for microorganism fractions or metabolites produced.

In the particular case of the compositions to be administered orally, the concentration of each microorganism and / or fraction and / or corresponding metabolite may be adjusted so as to correspond to doses (expressed in microorganism equivalent) ranging from 5.105 to 1013 cfu and in particular from 108 to 1011 cfu / day. A composition for topical application according to the invention may generally comprise from 103 to 10 12 cfu / g, in particular from 105 to 1010 cfu / g and more particularly from 10 to 109 cfu / g of microorganisms. When a composition comprises metabolites, the contents of metabolites in the compositions substantially correspond to the levels that can be produced by 103 to 1015 cfu, in particular 105 to 1015 cfu, and more particularly 10 to 1012 cfu of living microorganisms per gram. of support. The microorganism (s) can be included in a composition according to the invention in a living, semi-active or inactivated, dead form.

I1 (s) can also be included as fractions of cellular components or as metabolites. The microorganism (s), metabolite (s) or fraction (s) can also be introduced in the form of a freeze-dried powder, a culture supernatant and / or the where appropriate in a concentrated form. In the particular case of the topical compositions, it may be advantageous to use these microorganisms in inactivated or even dead form.

A composition according to the invention may be in any galenical form normally available for the chosen mode of administration. The support may be of a different nature depending on the type of composition considered. With particular reference to compositions for external topical administration, these may be aqueous, hydroalcoholic or oily solutions, solutions or dispersions of the lotion or serum type, emulsions of liquid or semi-solid consistency. liquid of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (O / W) or conversely (W / O), or suspensions or emulsions, of soft, semi-solid or solid consistency, of the cream type , aqueous or anhydrous gel, microemulsions, microcapsules, microparticles, or vesicular dispersions of ionic and / or nonionic type.

These compositions are prepared according to the usual methods. These compositions may include creams for cleaning, protection, treatment or care of lotions, gels or foams for the care of the skin, such as cleaning or disinfecting lotions, bath compositions or deodorant compositions. The compositions according to the invention may also consist of solid preparations constituting soaps or cleaning bars. They can also be used for the scalp in the form of solutions, creams, gels, emulsions, foams or in the form of aerosol compositions also containing a propellant under pressure. When the composition of the invention is an emulsion, the proportion of the fatty phase may range from 5 to 80% by weight, and preferably from 10 to 50% by weight relative to the total weight of the composition. The oils, emulsifiers and coemulsifiers used in the composition in emulsion form are chosen from those conventionally used in the cosmetics and / or dermatological field. The emulsifier and the coemulsifier may be present in the composition in a proportion ranging from 0.3 to 30% by weight, and preferably from 0.5 to 20% by weight relative to the total weight of the composition. When the composition of the invention is a solution or an oily gel, the fatty phase may represent more than 90% of the total weight of the composition. In known manner, the dosage forms dedicated to topical administration may also contain adjuvants which are usual in the cosmetic, pharmaceutical and / or dermatological field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, perfumes, fillers, filters, odor absorbers and dyestuffs. The amounts of these various adjuvants are those conventionally used in the field under consideration, and for example from 0.01 to 20% of the total weight of the composition. These adjuvants, depending on their nature, can be introduced into the fatty phase and / or into the aqueous phase. Fats which can be used in the invention include mineral oils such as, for example, hydrogenated polyisobutene and liquid petroleum jelly, vegetable oils such as, for example, a liquid fraction of shea butter, sunflower oil and almonds. apricot, animal oils such as perhydrosqualene, synthetic oils including Purcellin oil, isopropyl myristate and ethyl hexyl palmitate, unsaturated fatty acids and fluorinated oils such as perfluoropolyethers. It is also possible to use fatty alcohols, fatty acids such as, for example, stearic acid and, for example, waxes such as paraffin wax, carnauba wax and beeswax. It is also possible to use silicone compounds such as silicone oils and, for example, cyclomethicone and dimethicone, waxes, resins and silicone gums. As emulsifiers that can be used in the invention, mention may be made, for example, of glycerol stearate, polysorbate 60, the cetylstearyl alcohol / cetylstearyl alcohol mixture oxyethylenated with 33 moles of ethylene oxide sold under the name Sinnowax AO by Henkel, the mixture of PEG-6 / PEG-32 / glycol stearate sold under the name of Tefose 63 by Gattefosse, PPG-3 myristyl ether, silicone emulsifiers such as cetyldimethicone copolyol and sorbitan mono- or tristearate, stearate PEG-40, oxyethylenated sorbitan monostearate (200E). As solvents that can be used in the invention, mention may be made of lower alcohols, in particular ethanol and isopropanol, and propylene glycol. The composition of the invention may also advantageously contain a thermal and / or mineral water, especially chosen from Vittel water, Vichy basin water and Roche Posay water. As hydrophilic gelling agents, mention may be made of carboxylic polymers such as carbomer, acrylic copolymers such as copolymers of acrylates / alkyl acrylates, polyacrylamides and in particular the polyacrylamide mixture, C13-14-Isoparaffin and Laureth-7 sold under the name Sepigel 305 by the company SEPPIC, polysaccharides such as cellulose derivatives such as hydroxyalkylcelluloses and in particular hydroxypropylcellulose and hydroxyethylcellulose, natural gums such as guar, carob and xanthan and clays. Lipophilic gelling agents include modified clays such as bentones, metal salts of fatty acids such as aluminum stearates and hydrophobic silica, or ethylcellulose and polyethylene.

In the case of using a combination according to the invention orally, the use of an ingestible support is preferred. In the case of a use according to the invention orally, it favors the use of an ingestible support.

The unmanageable support may be of various nature depending on the type of composition considered. Examples of suitable foodstuffs or pharmaceuticals are tablets or lozenges, oral supplements in dry form and oral supplements in liquid form.

For example, they may be food supplements, the formulation of which may be carried out by the usual methods for producing, in particular, dragees, capsules, gels, emulsions, tablets, capsules and hydrogels allowing controlled release. In particular, the microorganism according to the invention can be incorporated into all other forms of food supplements or fortified foods, for example food bars or powders, compacted or not. The powders can be diluted in water, soda, dairy products or soy derivatives, or incorporated into food bars. A microorganism of the invention, one of its fractions and / or one of its metabolites, may be furthermore formulated with the usual excipients and components for such oral compositions or food supplements, namely in particular fatty components and / or aqueous, humectants, thickeners, preservatives, texture, flavor and / or coating agents, antioxidants, preservatives and dyes customary in the field of food. The formulating agents and excipients for oral composition, and especially for food supplements, are known in the art and are not the subject of a detailed description here. Examples of suitable food or pharmaceutical carriers are milk, yoghurt, cheese, fermented milks, fermented milk products, ice cream, cereal-based products or fermented cereal products, powders and the like. milk-based, formulas for children and infants, confectionery-type food products, chocolate, cereals, especially pet food, tablets, capsules, tablets, suspensions of liquid bacteria, oral supplements in dry form and oral supplements in liquid form.

Whatever the mode of administration considered, the effective amount of the microorganism of the invention, one of its fractions and / or one of its metabolites, can also be advantageously associated with at least one other active. Thus, a topical or oral composition, or an association according to the invention may further contain at least one active agent selected from an anti-seborrhoeic active agent, a moisturizing active agent, an antidandruff active agent and / or their mixtures.

Such a formulation advantageously makes it possible to amplify the beneficial effects of a microorganism of the invention. By anti-seborrhoeic active is meant a compound capable of regulating the activity of the sebaceous glands. An anti-seborrhoeic active agent that is suitable for the invention may, in particular, be chosen from retinoic acid, benzoyl peroxide, sulfur, vitamin B6 (or pyridoxine), selenium chloride, sea fennel; mixtures of cinnamon extract, tea and octanoylglycine such as Sepicontrol A5 TEA from Seppic; the mixture of cinnamon, sarcosine and octanoylglycine, marketed in particular by the company SEPPIC under the trade name Sepicontrol A5; zinc salts such as zinc gluconate, zinc pyrrolidone carboxylate (or zinc pidolate), zinc lactate, zinc aspartate, zinc carboxylate, zinc salicylate, zinc cysteate; copper derivatives and in particular copper pidolate such as Cuivridoné from Solabia; plant extracts of Arnica montana, Cinchona succirubra, Eugenia caryophyllata, Humulus lupulus, Hypericum perforatum, Mentha piperita, Rosmarinus officinalis, Salvia officinalis and Thymus vulgaris, all sold for example by the company MARUZEN; meadowsweet (Spiraea ulamaria) extracts, such as that sold under the name Sébonorminé by the company Silab; extracts of alga Laminaria saccharina such as that sold under the name Phloroginé by the company Biotechmarine; mixtures of extracts of burnet root (Sanguisorba officinalis / Poterium officinale), ginger rhizomes (Zingiber officinalis) and cinnamon bark (Cinnamomum cassia) such as that sold under the name Sebustop by the company Solabia; flax seed extracts such as that sold under the name Linuminé by Lucas Meyer; extracts of Phellodendron such as those sold under the name Phellodendron extract BG by the company Maruzen or Oubaku liquid B by the company Ichimaru Pharcos; mixtures of argan oil, Serenoa serrulata (saw palmetto) extract and sesame seed extract, such as that sold under the name Regu SEB by Pentapharm; mixtures of extracts of willowweed, Terminalia chebula, nasturtium and bioavailable zinc (microalgae) such as the product sold under the name Seborilys by Green Tech; extracts of Pygeum afrianum such as that sold under the name Pygeum afrianum sterolic lipid extract by the company Euromed; extracts of Serenoa serrulata such as those sold under the name Viapure Sabal by the company Actives International, or those sold by the company Euromed; mixtures of extracts of plantain, Berberis aquifolium and sodium salicylate such as the product sold under the name Seboclear by the company Rahn; clove extract such as that sold under the name Clove extract powder by Maruzen; argan oil such as that sold under the name Lipofructyl by Serobiological Laboratories; lactic protein filtrates, such as that sold under the name Normaseb by Sederma; extracts of Laminaria seaweed, such as that sold under the name Laminarghané by the company Biotechmarine; oligosaccharides of alga Laminaria digitata such as that sold under the name Phycosaccharide AC by the company Codif; cane sugar extracts such as the product marketed under the name Policosanol by Sabinsa; sulphonated shale oil, such as that sold under the name Ichtyol Pale by the company Ichthyol; extracts of ulmaria (spiraea ulmaria) such as that sold under the name Cytobiol Ulmaire by Libiol; sebacic acid, especially sold in the form of a sodium polyacrylate gel under the name Sebosoft by Sederma; glucomannans extracted from konjac tubers and modified with alkylsulphonate chains, such as the one sold under the name Biopol Betâ by the company Arch Chemical; extracts of Sophora angustifolia, such as those sold under the name Sophora powder or Sophora extract by the company Bioland; extracts from Cinchona succirubra bark such as that sold under the name Red bark HS by Alban Muller; extracts of Quillaja saponaria, such as that sold under the name Panama wood HS by Alban Muller; glycine grafted on an undecylenic chain, such as that sold under the name Lipacide UG OR by the company Seppic; the mixture of oleanolic acid and nordihydroguaiaretic acid, such as that sold in the form of a gel under the name AC.Net by Sederma; phthalimidoperoxyhexanoic acid; the trialkyl (Ci2-C13) citrate sold under the name COSMACOL ECI by the company Sasol; trialkyl citrate (C14-C15) sold under the name COSMACOL ECL by the company Sasol; 10-hydroxydecanoic acid, and especially mixtures of 10-hydroxydecanoic acid, sebacic acid and 1,10-decandiol such as that sold under the name Acnacidol BG by Vincience; and their mixtures.

The anti-seborrhoeic active agent is for example present in a content ranging from 0.1 to 10% by weight, preferably from 0.1 to 5% by weight, and preferably from 0.5% to 3% by weight, relative to the total weight of the composition. Anti-dandruff active means a compound capable of preventing the appearance of dandruff, reduce their number and / or make them disappear completely.

An anti-dandruff active agent that is suitable for the invention may, in particular, be chosen from: - pyridinethione salts, in particular calcium, magnesium, barium, strontium, zinc, cadmium, tin and zirconium salts . The zinc salt of pyridinethione is particularly preferred. The zinc salt of pyridinethione is especially marketed under the name Omadine zinc by OLIN. the trihalogéno carbamide of formula: Z ~~ NHCONH ~, ~ in which Z represents a halogen atom such as chlorine or a trihaloalkyl group C1-C4 such as CF3. triclosan represented by the formula: and and Cl OH - azole compounds such as climbazole, ketoconazole, clotrinazole, econazole, isoconazole and miconazole. antifungal polymers such as amphotericin B or nystatin. selenium sulphides, in particular those of formula SX Se 8_x, x ranging from 1 to 7. sulfur in its various forms, cadmium sulphide, allantoin, coal tar or wood tar and their derivatives in particular cade oil, salicylic acid, undecylenic acid, fumaric acid, allylamines such as terbinafine. As preferred examples of antidandruff agents, there may be mentioned zinc pyrithione, salicylic acid, selenium disulfide, and mixtures thereof. A composition according to the invention advantageously comprises from 0.001 to 10% by weight of anti-dandruff agent (s), preferably from 0.1 to 5% by weight, even more preferably from 0.2 to 2% by weight. , relative to the total weight of the composition. A moisturizing active agent is an active agent capable of reducing the dry state of an epidermis. Moisturizing active agent is understood to mean: either a compound acting on the barrier function, with a view to maintaining the hydration of the stratum corneum, or an occlusive compound. There may be mentioned ceramides, compounds based on sphingoids, lecithins, glycosphingolipids, phospholipids, cholesterol and its derivatives, phytosterols (stigmasterol, 13-sitosterol, campesterol), essential fatty acids, 1-2 diacylglycerol, 4-chromanone, pentacyclic triterpenes, petrolatum, and lanolin; or a compound directly increasing the water content of the stratum corneum, such as urea and its derivatives, thralose and its derivatives, hyaluronic acid and its derivatives, glycerol, pentanediol, pidolates, serine, xylitol, lactic acid and sodium lactate, glycerol polyacrylate, ectoin and its derivatives, chitosan, oligo- and polysaccharides, cyclic carbonates, N-lauroyl pyrrolidone carboxylic acid, and Na- benzoyl-L-arginine. or a compound that activates the sebaceous glands such as steroid derivatives (including DHEA) and vitamin D and its derivatives. These compounds may represent from 0.001% to 30%, and preferably from 0.01% to 20%, of the total weight of the composition according to the invention.

By way of illustration of the urea derivatives, mention may be made more particularly of the hydroxyalkyl urea derivatives and in particular those described in the document FR 2 877 222.

The topical or oral compositions, or combinations according to the invention may also contain, as an additional asset, an active ingredient intended in particular to reinforce the cutaneous barrier. As active agents that may be mentioned include vitamins A, B3, B5, B6, B8, C, D, E, or PP, curcuminoids, carotenoids, polyphenol and mineral compounds, sugars, amino acids , sulfur amino acids, polyunsaturated fatty acids 3 and 6, taurine and phytosterols. In particular, it is possible to use an antioxidant complex comprising vitamins C and E, and at least one carotenoid, in particular a carotenoid chosen from 13-carotene, lycopene, astaxanthin, zeaxanthin and lutein, flavonoids such as catechins, proanthocyanidins, anthocyanins, ubiquinones, coffee extracts containing polyphenols and / or diterpenes, chicory extracts, ginkgo biloba extracts, proanthocyanidin-rich grape extracts, pepper extracts, soy extracts, other sources of flavonoids with antioxidant properties, fatty acids, prebiotics, taurine, resveratrol, amino acids of selenium, glutathione precursors. Among the flavonoids, catechins and OPCs (procyanidolic oligomers) are preferably chosen. It can also be at least one prebiotic or a mixture of prebiotics. More particularly, these prebiotics can be chosen from oligosaccharides, produced from glucose, galactose, xylose, maltose, sucrose, lactose, starch, xylan, hemicellulose, inulin, acacia-type gums, for example, or of their mixtures. More particularly, the oligosaccharide comprises at least one fructooligosaccharide. More particularly, this prebiotic may comprise a mixture of fructo-oligosaccharide and inulin. In the topical dosage forms, proteins or protein hydrolysates, amino acids, polyols, especially C 2 to C 10 polyols such as glycerol, sorbitol, butylene glycol and polyethylene glycol, urea allantoin, sugars and sugar derivatives, water-soluble vitamins, starch, bacterial or plant extracts such as Aloe Vera. With regard to lipophilic active agents, it is possible to use retinol (vitamin A) and its derivatives, tocopherol (vitamin E) and its derivatives, ceramides, essential oils and unsaponifiables (tocotrienol, sesamin, gamma oryzanol, phytosterols, squalens, waxes, terpenes). As active agents that are also capable of being associated with the microorganism of the invention, with one of its fractions and / or with one of its metabolites, in an oral dosage form, it is also possible to consider all the ingredients commonly used and / or allowed. By way of illustration, mention may be made of vitamins, minerals, essential lipids, trace elements, polyphenols, flavonoids, phytoestrogens, antioxidants such as lipoic acid and coenzyme Q10, carotenoids, prebiotics, proteins and amino acids, mono- and polysaccharides, aminosugars, phytosterols and triterpene alcohols of plant origin. These are, in particular, vitamins A, C, D, E, PP and group B. Of the carotenoids, beta-carotene, lycopene, lutein, zeazanthin and astaxanthin are preferably selected. . The minerals and trace elements particularly used are zinc, calcium, magnesium, copper, iron, iodine, manganese, selenium, chromium (III). Among the polyphenol compounds, polyphenols of grape, tea, olive, cocoa, coffee, apple, blueberry, elderberry, strawberry, cranberry, and onion are also particularly preferred. Preferably, among the phytoestrogens, isoflavones are retained in the free or glycosylated form, such as genistein, daidzein, glycitein or lignans, in particular those of flax and schizandra chinensis. Amino acids or peptides and proteins containing them, such as taurine, threonine, cysteine, tryptophan, methionine. The lipids preferably belong to the group of oils containing mono and polyunsaturated fatty acids such as oleic, linoleic, alpha-linolenic, gamma-linolenic, stearidonic, long-chain omega-3 fatty acids such as EPA and DHA, conjugated fatty acids derived from plants or animals such as CLA (Conjugated Linoleic Acid). Thus, particularly when a microorganism of the invention, one of its fractions and / or one of its metabolites, is intended for oral administration, it may be furthermore associated with at least one nutritional asset. selected from lycopene, vitamin C, vitamin E and polyphenol compounds.

A microorganism of the invention, one of its fractions and / or one of its metabolites, or an association according to the invention, can also be combined with other nutritional active ingredients chosen from: age, such as food antioxidants, nutrients with anti-radical properties and cofactors of endogenous antioxidant enzymes, vitamins A, C, E, carotenoids, xantophyls, isoflavones, certain minerals such as zinc, copper, magnesium, selenium, lipoic acid, coenzyme Q10, superoxide dismutase (SOD) or taurine. Antiaging agents that may be mentioned include unsaponifiable fractions extracted from plant-derived lipids, aloe vera, native or hydrolyzed marine collagen, vegetable or marine oils rich in omega-3 fatty acids, omega-6 fatty acids (including gamma-linolenic acid), - the photoprotective nutritional assets such as: antioxidants and antiradicals: vitamins A, C, E, carotenoids, xantophyls, certain minerals such as zinc, copper, magnesium, selenium, coenzyme Q10, superoxide dismutase (SOD), - nutritional ingredients with moisturizing or immunomodulatory properties such as polypodium leucotomos extract, vegetable or marine oils rich in omega-3 fatty acids, omega -6, including gamma-linolenic acid. A cosmetic treatment method of the invention may be implemented in particular by administering the cosmetic and / or dermatological compositions or combinations as defined above, according to the usual technique of use of these compositions. For example: applications of creams, gels, serums, lotions, cleansing milks or after-sun compositions on the keratin material such as dry skin or hair, application of a hair lotion to wet hair or of shampoos for topical application. A cosmetic process according to the invention can thus be carried out by topical, daily administration for example of a composition considered according to the invention. A method according to the invention may comprise a single administration. According to another embodiment, the administration is repeated, for example, 2 to 3 times daily over a day or more and generally over an extended period of at least 4 weeks, or even 4 to 15 weeks, with, where appropriate, one or several periods of interruption. In the following description and examples, unless otherwise stated, percentages are percentages by weight and ranges of values in the form between ... and ... include the specified lower and upper bounds. The ingredients are mixed, before they are shaped, in the order and under conditions easily determined by those skilled in the art. The content and the nature of the ingredients used in the compositions of the invention are adjusted by those skilled in the art so as not to substantially affect the properties required for the compositions of the invention.

The following examples are presented by way of illustration and not limitation of the field of the invention.

FIGURES Figure 1: illustrates the clinical evaluation of the presence of free skin in individuals treated with Maltodextrin (A) or 1x109 cfu / g Lactobacillus paracasei ST11 (CNCM I-2116 (B)) Figure 2: illustrates the assessment clinical study of the presence of adherent film on individuals treated with Maltodextrin (A) or 1x109 cfu / g Lactobacillus paracasei ST11 (CNCM I-2116) (B) Figure 3: illustrates the clinical evaluation of erythema in patients with individuals treated with Maltodextrin (A) or 1x109 cfu / g Lactobacillus paracasei ST11 (CNCM I-2116) (B).

Figure 4: illustrates the results of measurement of the presence of yeast Malassezia sp. in individuals treated with Maltodextrin (A) or 1x109 cfu / g Lactobacillus paracasei ST11 (CNCM I-2116) (B). EXAMPLES Example 1: Stick powder Active ingredient Lactobacillus paracase® ST11 1010 ufc Excipient Xanthan gum 0.8 mg Sodium benzoate 0.2 mg Maltodextrin qs 30 g One stick per day can be taken.

EXAMPLE 2 Stick Powder Active Principle Lactobacillus Paracase® ST1110 UFc Excipient Xanthan Gum 0.8 mg Sodium Benzoate 0.2 mg Maltodextrin qsp 30 g One stick per day can be taken.

Example 3: Dragée-type formulation Active ingredients mg / tablet Lactobacillus paracase® ST11 5,10 'cfu Excipient of the dragee nucleus Microcrystalline cellulose 70 Encompressor 60 Magnesium stearate 3 Anhydrous colloidal silica 1 Coating agent Shellac 5 Talc 61 Sucrose 250 Polyvidone 6 Titanium Dioxide 0.3 Coloring Agent 5 type of ripe dragee can be taken 1 to 3 times a day.

EXAMPLE 4 Formulation of the drageous type Active ingredients mg / tablet Lactobacillus paracasei ST11 109 cfu Lactobacillus johnsonii 109 cfu Excipient of the dragee core Microcrystalline cellulose 70 Encompressor 60 Magnesium stearate 3 Colloidal anhydrous silica 1 coating agent Shellac 5 Talc 61 Sucrose 250 Polyvinylidone 6 Titanium dioxide 0.3 Coloring agent 5 This type of candy can be taken 1 to 3 times a day. EXAMPLE 5 Lotion for the scalp% by weight Lactobacillus paracase® powder ST11 5.00 Lactobacillus jonhsonii powder 5.00 Antioxidant 0.05 Isopropanol 40.0 Preservative 0.30 Water qs 100 26 Example 6: Milk for the care of the scalp scalp% by weight Powder of Lactobacillus paracasei ST11 5.00 Glycerol stearate 1.00 Cetylstearyl alcohol oil / cetylstearyl alcohol oxyethylenated at 30 mole EO (Sinnowax A0 sold by HENKEL) 3.00 Cetyl alcohol 1.00 Dimethicone (DC 200 Fluid sold by DOW CORNING) 1.00 Vaseline oil 6.00 Isopropyl myristate (Estol IMP 1514 sold by UNICHEMA) 3.00 Antioxidant 0.05 Glycerin 20.00 Preservative 0.30 Water qs 100

EXAMPLE 7 Scalp Care Gel% by weight Lactobacillus paracase® powder ST11 5.00 Hydroxypropylcellulose (Klucel H sold by the company 5.00 HERCULES) 1.00 Vitamin E 2.50 Antioxidant 0.05 Isopropanol 40.00 Preservative 0.30 Water qs 100 27 Example 8: Milk for the care of the scalp% by weight Lactobacillus paracase® powder ST11 5.00 Glycerol stearate 1.00 Cetyl stearyl alcohol / cetylstearyl alcohol oxyethylenated at 3 mole EO (Sinnovax A0 sold by HENKEL) 3,00 Cetyl alcohol 1,00 Dimethicone (DC 200 Fluid sold by Dow Corning) 1,00 Vaseline oil 6,00 Isopropyl myristate (Estol IPM 1514 sold by Uniqema) 3,00 Glycerine 20.00 Preservative 0.30 Water qs 100

EXAMPLE 9 Scalp Care Cream% by weight Arachidyl behenyl alcohol / arachidylglusoside 3.0 Isohexadecane 7.0 Lactobacillus paracasei powder ST11 5.00 Glycerin 2.0 Vitreoscilla filiformis extract 3.0 BHT 0.05 methyl POB 0.1 POB propyl 0.05 Water qs 100 2938429 28 Example 10: Gel for the care of the hair% by weight Powder of Lactobacillus paracasei ST11 5.00 Copper citrate 2.00 Extract of Vitreoscilla filiformis 3.00 Antioxidant 0.05 Vitamin C 2.50 Antioxidant 0.05 Isopropanol 40.00 Preservative 0.30 Water qs 100 Example 11: Efficiency study Protocol 15

An oral composition based on probiotic microorganism (B) has been tested for its effectiveness vis-à-vis the dandruff and seborrheic dermatitis of the scalp with regard to a placebo composition (A). The compositions are of the following formulation: A: Maltodextrin B: 1x109 cfu / g Lactobacillus paracasei ST11 NCC 2461 (CNCM I-2116) The treatment consists in administering a single quantity of treatment daily and orally for a period of eight weeks ( 56 days). 25 This study was conducted in 66 adult male subjects aged between 18 and 60 years who were identified following a clinical assessment of their moderate to severe dermal condition with scores greater than or equal to 3 (on a scale of 0 to 4) in the presence of adherent scales on at least two quarters of the head. In the clinical evaluation, the presence of erythema and seborrheic dermatitis of the scalp were also taken into account. The 66 subjects were divided into two parallel groups of 33 subjects, with one group receiving the tested product and one group receiving the placebo.

The effect of the complement tested is assessed by comparison with the placebo formulation at JI, J15, J29, J43, J57 and J64 (after one week of stopping treatment), through clinical evaluations and self-assessments performed on the following parameters: free dandruff, adherent scales, erythema and seborrhea of the scalp, seborrhea of the face and pruritus. The clinical parameters evaluated are the presence of free and adherent dandruff, the presence of scales, erythema, seborrhea of the face and scalp, as well as the measurement of the presence of yeast Malassezia sp .. These evaluations are carried out according to the techniques usually employed in the field. The parameters self-assessed by the individuals treated are the presence of dandruff, pruritus, the sensation of fatty state, irritation, redness, the feeling of tightness and the perception of the scalp, as well as seborrhea of the face and hair . The results obtained show a significant improvement, from the first weeks of treatment, in dandruff, erythema and seborrheic dermatitis of the scalp in subjects treated with composition B compared to subjects taking the placebo.

These evaluations were supplemented by enumeration of yeasts of the genus Malassezia sp. at the level of the scalp.

Results A = Placebo (maltodextrin) B = Lactobacillus paracasei, NCC 2461 (ST11) 10 9 cfu / d

1. Clinical evaluation: a. Free films The results illustrated in FIG. 1 show a decrease in free films versus placebo in trend from day 15 (p = 0.057), significant at day 29 and up to day 57 (p <0.0001).

The change between J1 and J57 is significant in favor of the asset (p = 0.0005). One week after stopping treatment, on D64, the efficacy is maintained versus placebo between D1 and D64 (p = 0.0489). b. Adherent films The results illustrated in Figure 2 show a significant decrease of adherent films versus placebo from D29 to D57 (p <0.0001). The change between J1 and J57 is significant in favor of the asset (p = 0.0005). vs. Erythema The results illustrated in Figure 3 show a significant decrease in erythema versus placebo from D29 to D57 (p = 0.0015). The change between J1 and J57 is significant in favor of the asset (p = 0.00469). A total maintenance of the effectiveness of the composition of the invention is observed between J57 and J64 with regard to this clinical aspect.

2. Self-evaluations: The results obtained in self-evaluation show the same type of profiles as those observed in clinical evaluation for the different parameters studied. In particular, the effectiveness of the active against pruritus is observed with a significant effect between Jl and J57 versus placebo (p = 0.0427). In the same way, the volunteers judged the decrease of the fatty state of their scalp as very important and significant between Jl and J57 versus placebo (p = 0.0300). For facial seborrhea, a trend towards J57 versus placebo was observed in favor of the probiotic with a decrease in seborrhea (p = 0.1735).

3. Malassezia sp: The results illustrated in Figure 4 show a significant decrease of the Malassezia sp for the product versus placebo as of J15 (p = 0.0237). The evolution between J1 and J57 is significant for the active (p = 0.0272) whereas there is no variation between J1 and J57 for the placebo.

One week after treatment, on day 64, the efficacy of the product is maintained (trend effect versus placebo p = 0.2312).

Claims (16)

REVENDICATIONS1. Cosmetic use of an effective amount of at least one probiotic microorganism, in particular of the genus Lactobacillus and / or Bifidobacterium sp., Of one of its fractions and / or of one of its metabolites, as an agent for preventing and / or or treat disorders of the scalp. 2. Use according to claim 1, wherein said microorganism is intended to prevent and / or treat a dandruff condition of the scalp. 3. Use according to claim 1, wherein said microorganism is intended to improve the comfort of the scalp. 4. Use according to claim 1, wherein said microorganism is intended to restore a balanced ecoflora of the scalp. 5. Use according to claim 1, wherein said microorganism is intended to preserve and / or enhance the integrity of the barrier functions of the skin of the scalp. 6. Use according to claim 1, wherein said microorganism is intended to prevent and / or treat seborrheic pruritus and / or dermatitis of the scalp. 7. Use according to any one of the preceding claims, wherein the microorganism is chosen from Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus paracasei, Lactobacillus casei, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium animalis, Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium adolescentis or Bifidobacterium pseudocatenulatum, and mixtures thereof. Use according to any one of the preceding claims, wherein the microorganism is Lactobacillus paracasei. 9. Use according to any one of the preceding claims, wherein the microorganism is Lactobacillus paracasei CNCM I-2116. 10. Use according to any one of the preceding claims, wherein said microorganism is carried out in a proportion of 0.0001 to 20% by weight, in particular from 0.001 to 15% and more particularly from 0.01 to 10% by weight. weight and especially from 0.1 to 2% by weight relative to the total weight of the composition containing it. 11. Use according to any one of the preceding claims, wherein said microorganism is carried out topically or orally. Use according to any one of the preceding claims, wherein said microorganism is a first microorganism of the genus Lactobactillus in association with at least an effective amount of at least a second distinct microorganism to said first microorganism. 13. Use according to the preceding claim, wherein said second microorganism is selected from ascomycetes such as Saccharomyces, Yarrowia, Kluyveromyces, Torulaspora, Schizosaccharomyces pombe, Debaromyces, Candida, Pichia, Aspergillus and Penicillium, bacteria of the genus Bifidobacterium, Bacteroides, Fusobacterium , Melissococcus, Propionibacterium, Enterococcus, Lactococcus, Staphylococcus, Peptostrepococcus, Bacillus, Pediococcus, Micrococcus, Leuconostoc, Weissella, Aerococcus, Oenococcus, Lactobacillus, and mixtures thereof. 14. Use of an effective amount of at least one probiotic microorganism, especially of the genus Lactobacillus and / or Bifidobacterium sp. and / or a fraction thereof and / or a metabolite thereof for preparing a pharmaceutical or dermatological composition for preventing and / or treating inflammation of the scalp. 15. Cosmetic and / or dermatological composition, useful for preventing and / or treating disorders of the scalp, comprising in a physiologically acceptable medium, at least one effective amount of at least one probiotic microorganism, in particular of the genus Lactobacillus and / or Bifidobacterium sp. and / or one of its fractions and / or one of its metabolites, in combination with an effective amount of at least one active agent selected from an anti-dandruff active, a moisturizing active agent, and mixtures thereof. 16. Cosmetic process for treating and / or preventing aesthetic disorders of the scalp in a subject comprising at least one step of administering to said subject, at least one effective amount of at least one probiotic microorganism, in particular of the genus Lactobacillus and and / or Bifidobacterium sp., and / or a fraction thereof and / or one of its metabolites.